A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2011
At a glance
- Drugs Erlotinib; OSI 930
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 08 Jul 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
- 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.